Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life
Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, Merve Atli, James C Bennett, Megan Croal, Charles DeBattista, Boadie W Dunlop, David Feifel, David J Hellerstein, Muhammad Ishrat Husain, John R Kelly, Molly R Lennard-Jones, Rasmus W Licht, Lindsey Marwood, Sunil Mistry, Tomáš Páleníček, Ozlem Redjep, Dimitris Repantis, Robert A Schoevers, Batya Septimus, Hollie J Simmons, Jair C Soares, Metten Somers, Susan C Stansfield, Jessica R Stuart, Hannah H Tadley, Nisha K Thiara, Joyce Tsai, Mourad Wahba, Sam Williams, Rachel I Winzer, Allan H Young, Matthew B Young, Sid Zisook, Ekaterina Malievskaia
Journal of Affective Disorders February 3, 2023 DOI: 10.1016/j.jad.2023.01.108 via OpenAlex
Summary
AI-generated from the abstractThree weeks after a single dose, 25 mg of psilocybin, and to a lesser extent 10 mg, improved patient-reported measures of depression severity, anxiety, affect, and functioning in people with treatment-resistant depression. These findings extend the primary results from the largest randomized clinical trial of psilocybin for TRD, highlighting outcomes that matter to patients.
Study at a glance
| Characteristics | Randomized clinical trial Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Intervention | Psilocybin |
| Dose | 25 mg, 10 mg |
| Duration | Three weeks after dosing |
| Topics | Anxiety Depression Psilocybin |
| Keywords | Antidepressant Patient-reported outcomes Psychedelic treatment |
| Citations | 168 |
| Key finding | Psilocybin 25 mg and, to a lesser degree, 10 mg improved patient-reported depression severity, anxiety, affect, and functioning three weeks after dosing. |
Abstract
Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning. These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.